Showing posts with label prescribing. Show all posts
Showing posts with label prescribing. Show all posts

Tuesday, June 27, 2023

Hippocrates the Projective Test

 



There is no doubt that the ancient physician Hippocrates was an advanced thinker in terms of medicine and its conceptualization. He is widely credited with advancing nosology and diagnostics as well as professionalism. In the field of medicine, he was studied right up until the turn of the 19th century by physicians who attended medical schools in Europe.  Like all prominent figures from the past there is a question of whether invoking Hippocrates these days represents idealization or rhetoric more than his accurate historical position. 

I am referring specifically to a blog by Nassir Ghaemi, MD entitled Hippocratic Psychopharmacology.  After correcting the aphorism “First do no harm” to “As to diseases, try to help, or at least not harm.” he elaborates on a few ideas from Hippocrates and the implications for modern medicine. He interprets the preamble of Hippocrates statement to mean that diseases must be identified and if you cannot or will not take the disease concept seriously you cannot help anyone as a doctor. He emphasizes that there should be a focus on not doing any harm and that overall treatment should be conservative. He acknowledges a bias that too many medications are being used in modern times.

Hippocrates additional idea is that diseases are a natural process and they heal naturally and physicians should not get in the way of that process. He discusses self-limited, treatable, and incurable diseases suggesting only the treatable illnesses are a focus for physicians.

Hippocrates was apparently not enough so Holmes Rules and Osler’s rule are added. The explanation of Holmes Rules is inconsistent because initially it described prescribing based on benefits first and harms second, but in the elaboration the assumption is supposed to be that the medication is harmful. If that is your assumption harms would seem to be prioritized.  Here is an excerpt from the post from 1861:

“……I firmly believe that if the whole materia medica, as now used, could be sunk to the bottom of the sea, it would be all the better for mankind, – and all the worse for the fishes.”

In other words, if you wanted to prescribe something – there is nothing useful to prescribe and given the time frame - that is correct.  1861 was before the discovery of germ theory.  Of the estimated 750,000 Civil War (1861-1865) deaths at the time about 2/3 died of diseases that are treatable in modern times. The only effective medical treatments at the time were citrus fruits and vegetables to prevent scurvy, smallpox vaccines, and quinine for malaria. Four types of wound infections were described including tetanus, erysipelas, hospital gangrene, and pyemia or sepsis with mortality rates of 46-90%.  Since there were no antibiotics infected wounds were treated with repeated debridement or amputation with the hope that remaining healthy tissue would generate an inflammatory and healing response. 

In his writings, Hippocrates describes many forms of orthopedic treatment and general medical treatment for infections including gangrene and erysipelas. Those afflictions were not likely to heal without significant medical and surgical interventions. I suppose in keeping with the stated philosophy they could be reclassified as “untreatable.” The question might become were untreatable diseases less treatable in Hippocrates time than during the Civil War? Either way it is likely that Hippocrates watched at least as many of his patients die as Civil War surgeons did and those were very high mortality rates.

Ghaemi uses the example of antidepressants in bipolar disorder as breaking Holmes Rule “egregiously.” Unfortunately, the presentation of bipolar disorder may not be that clear cut.  As a tertiary care psychiatrist, it was common to see people experience manic episodes after years of treatment for unipolar depression with antidepressants or even as an antidepressant is tapered and discontinued. You must have seen a manic episode along the way in order make the diagnosis and stop the antidepressant.  It also helps if the patient is under the care of a psychiatrist and it is likely the vast number of antidepressants in these presentations were prescribed by other specialists or nonphysicians. I have never heard of a psychiatrist needing more evidence to stop antidepressants in bipolar disorder.  It was done routinely by my colleagues in acute care.

Osler is quoted in the discussion of Osler’s Rule:

“A man cannot become a competent surgeon without a full knowledge of human anatomy and physiology, and the physician without physiology and chemistry flounders along in an aimless fashion, never able to gain any accurate conception of disease, practicing a sort of popgun pharmacy, hitting now the malady and again the patient, he himself not knowing which.”

And what exactly was known in Osler’s time about pathophysiology and pharmacotherapy?  Probably not much more than was known at the time of the Civil War.  Paton’s reference (5) contains several additional quotes to illustrate what he describes as Osler’s nihilism including that there were no useful treatments for scarlet fever, pneumonia, and typhoid fever.  Diarrhea and dysentery were common in soldiers leading to both compromised health status and death.  A summary quote from Osler’s time suggests there were only a few useful treatments including iron for anemia, quinine for malaria, mercury and potassium iodide for syphilis and that there were no other drugs supported by experimental evidence.  It turns out that that the evidence for potassium iodide in syphilis was restricted to reducing inflammation in some late-stage lesions since it was not an anti-spirochetal agent (4).

If Osler was aware of a potentially effective drug – he may have pushed it beyond what his colleagues were using as evidenced in this quote:

'At times of crisis Sir W. Osler and others have pressed up the nitrites to huge doses, in persons upon which these drugs had been well tested. Sir William said he had never seen harm come of large doses if cautiously approached. I think he used to speak of 20-30 grains of sodium nitrite per diem. I have administered half as much in a day.' (pp 88-9).” (3)

20-30 grains of sodium nitrite is roughly equivalent to 1,329 to 1,980 mg.  In a 70 kg patient that would be 19-28.3 mg/kg.  The worrisome complication from nitrites is methemoglobinemia. In severe cases it can result in coma, cardiac arrythmias, and death. PubChem suggests that intravenous doses of 2.7 – 8 mg/kg can be problematic. A leading toxicology text suggests that when sodium nitrite is given intravenously to treat cyanide poisoning the dose is 300 mg given at a rate of 75-150 mg/minute intravenously with a repeat dose at half the amount if necessary, monitoring for symptoms of nitrite toxicity. While it is difficult extrapolating oral toxicity from IV administration there are reports of life threatening and fatal oral ingestions resulting from taking 12.5-18 g of sodium nitrite. The EPA recommends limiting exposure to 1.0 mg/kg/day. All of this toxicology information suggests the the doses that Osler was using were pushing the limit, but it also points to another deficiency in suggesting that his parsimony (or nihilism) is a touchstone for modern physicians.  That deficiency is that his outcomes were unknown. The case reports that I have found were generally limited to a case or two. I could not find any outcomes for high dose versus low dose nitrites for angina or congestive heart failure. Modern nitrate preparations such as isosorbide mono and di-nitrates are limited by tolerance to the vasodilating effect. I may be wrong but I speculate the Osler knew very little about the pharmacology of nitrites and the mechanisms of tolerance and toxicity.

A common theme for these conservative historical pharmacologists is that it is easy to be conservative when there are no known effective treatments.  When your category of treatable diseases is small – it is easy to rationalize watching the self-limited and untreatable illnesses run their course.  There was a very long period of slow progress in therapeutics between the time of Hippocrates (460-375 BCE) and Osler (1849-1914). Penicillin was not available to treat syphilis until 1943. Even though there was some basic science research in pharmacology in the mid 19th century, Paton’s review shows that potentially effective medications, in pill form and in significant numbers did not occur until about 1920.

Apart from limited therapeutic options, the doctrine of informed consent was either nonexistent or much less clear in earlier times.  Gutheil and Applebaum (6) trace the early evolution and consolidation as occurring in the 1950s and 1960s in the US.  The earliest clear application was for surgery and invasive treatments extending to medical treatments.  In psychiatry, that also extended to medication treatment and neuromodulation but at the time of this book whether it was necessary for psychotherapy or not was not clear.  To me one of the clearest reasons for informed consent is the level of uncertainty in medicine. We know probabilities at the population level but are rarely able to predict side effects and adverse reactions at the individual level.  I have written about my approach to this problem on this blog and it is basically a shared decision-making model where the patient is informed of the uncertainty of both efficacy and adverse events as clearly as possible. That information was not available to to earlier physicians. Detailed regulatory information in package inserts is a relatively recent phenomena starting in 1968 in the US with several modifications since then.  

Ghaemi winds down his critique emphasizing diagnoses over symptoms.  He uses the bipolar disorder example again and hedges suggesting that is it acceptable to treat symptoms sometimes but there are no guidelines only the rather extreme criticism that by treating diseases and developing a Hippocratic psychopharmacology we can avoid the “eclectic mish-mash which is contemporary psychiatry.”

It is apparent to me that Hippocrates and Osler have very little to offer present day psychopharmacologists. They both a had very large body of patients who could not be treated. Both had limited evidence-based pharmacopeias and both prescribed toxic compounds with no clear guidelines or suggestion of efficacy. On diseases, syndromes, and symptoms – the issues are much clearer these days but much is still written about how these concepts are confusing. That is especially true in psychiatry where decades of debate has not resulted in any more clarity.  It is not as easy to separate out insomnia, anxiety, and mood disturbance with bipolar disorder as Ghaemi makes it seem, but treating them all at once in a single point of time is probably not the best approach. In clinical practice at least some people have insomnia, anxiety disorders, and depression prior to the onset of any diagnosis of bipolar disorder. Assuming adequate time to make those historical diagnoses, there are no clear guidelines about what should be treated first and no clinical guidelines on when medications should be started and stopped.  It all comes down to the judgement and experience of the physician and patient consent and preference. Evidence based medicine advocates always argue for that approach but it it highly unlikely that there will be clinical trials for every scenario and the trials that do occur are often limited by inclusion and exclusion criteria.   Hippocrates and Osler have no better guidance.

As therapeutics has evolved, polypharmacy has become a part of the clinical environment of all specialists.  It is common to see patients taking multiple medications in order to treat their cumulative diseases, even before a psychiatric medication is prescribed. Despite all of the rhetoric – I am convinced that experts can manage polypharmacy environments if they need to and do it with both therapeutic efficacy and minimal to no side effects.  

For the record, I agree with Ghaemi’s overall message that you need good indications for medical treatments and that the fewer medications used the better. Those decisions need to incorporate, current evidence, informed consent, and frequent detailed follow up visits to reduce the risks of inadequate treatment and adverse events. That is hard work - not helped by guidance from the ancients or modern-day philosophers.

 

George Dawson, MD, DFAPA

 

References:

1:  Ghaemi N. Hippocratic Psychopharmacology.  Jun 16, 2023. https://psychiatryletter.com/hippocratic-psychopharmacology/

2:  Burns SB.  Civil War Disease and Wound Infection https://www.pbslearningmedia.org/resource/ms17.socct.cw.disinf/civil-war-disease-and-wound-infection/  Accessed on 06.20.2023

3:  Paton W. The evolution of therapeutics: Osler's therapeutic nihilism and the changing pharmacopoeia. The Osler oration, 1978. J R Coll Physicians Lond. 1979 Apr;13(2):74-83. PMID: 374726; PMCID: PMC5373168.

4:  Keen P. Potassium iodide in the treatment of syphilis. Br J Vener Dis. 1953 Sep;29(3):168-74. doi: 10.1136/sti.29.3.168. PMID: 13094013; PMCID: PMC1053890.

5:  Howland MA.  Nitrite (amyl and sodium) and sodium thiosulfate.  In:. Nelson LS, Howland M, Lewin NA, Smith SW, Goldfrank LR Hoffman RS (eds). Goldfrank’s Toxicologic Emergencies. McGraw-Hill Education; 2019. P. 1698-1701.

6:  Gutheil TG, Appelbaum PS.  Clinical Handbook of Psychiatry and the Law, 3rd ed. Lippincott, Williams and Wilkins; 2000; Philadelphia, PA: 154-157.

7:  Writings of Hippocrates. Translated by Francis Adams. Excercere Cerebrum Publications; 2018.

 

 

Graphics Credits:

 

William Osler aged 32: Notman photographic archives, Public domain, via Wikimedia Commons.  https://upload.wikimedia.org/wikipedia/commons/e/e9/William_Osler_1881.jpg

Hippocrates: ESM, CC BY-SA 4.0 <https://creativecommons.org/licenses/by-sa/4.0>, via Wikimedia Commons. https://upload.wikimedia.org/wikipedia/commons/8/82/Facultat_de_Medicina_de_la_Universitat_de_Barcelona_-_Hip%C3%B2crates_de_Kos.jpg

Wednesday, December 7, 2022

What drugs should psychiatrists prescribe?

 


That was a question posed by a recent paper in Academic Psychiatry (1).  The focus was on psychopharmacology agents from the perspective of older agents like lithium, monoamine oxidase inhibitors (MAOIs), and tricyclic antidepressants (TCAs).  Every few years, the debate about these drugs is rekindled – almost like the stereotypical old man shouting: “Hey you kids – get off my lawn.”   Should psychiatrists know how to prescribe older agents – of course they should. First off, the age of the agent has nothing to do with efficacy. Lithium is the best example there and it continues to have the best efficacy for bipolar disorder relative to new agents.  TCAs and MAOIs have comparable efficacy to newer antidepressants like selective serotonin reuptake inhibitors (SSRIs) but given the span of clinical trials – a strict comparison is not possible. Some authors do make unequivocal statements about both TCAs and MAOIs having superior efficacy to SSRIs. But in my opinion meta-analyses does not eliminate the differences in clinical trials technology over the past 50 years.

The authors make some of these arguments and suggest a number of biases that may be operating against prescribing these medications. Some of those biases originate in risk perception. In general, newer medications do tend to be safer.  They are certainly not without risk.  Serotonin syndrome and neuroleptic malignant syndrome are the typical rare but high-risk complications of prescribing psychiatric medications but there are many more. The rational discussion of risk involves knowing the pharmacology, knowing any risk mitigation strategies, knowing to what extent your patient can co-manage that risk with you, and the explicit informed consent discussion outlining the risks.

In my experience about 15-20% of outpatients do not tolerate modern antidepressants well at all. I have always encouraged people in that situation to try something different. TCAs and MAOIs are certainly not devoid of side effects but it is possible to change to one of those medications and the patient notices immediately that the drug is well tolerated and eventually effective.  Clinical trial data will show that as a group SSRIs are safer and better tolerated than either TCAs or MAOIs but in the clinic we are treating individuals and not groups.  On an individual basis, people are selected based on whether they tolerate a class of medications or not and that does not mean that they will not tolerate all medications.  With lithium, MAOIs, and TCAs – the informed consent discussion needs to include the potential toxicities with reassurances that the goal is to avoid side effects and complications. 

That has been my approach to psychopharmacology for 35 years. It was easier for me to have this perspective because when I started out back in 1986, the only antidepressants available were TCAs and MAOIs. I also trained with two psychiatrists, James Jefferson and John Greist who wrote the Lithium Encyclopedia and ran the Lithium Information Center.  In the days prior to the internet, it was a repository of all known hard copy references to lithium in the medical literature. There were additional formative experiences, most notable 22 years on acute care units where you are the person responsible for the total medical and psychiatric care of the patient. It was common to see patients on multiple psychiatric and nonpsychiatric medications with varying levels of adherence and instability. In some cases, they were accompanied by several shopping bags of medications and it was impossible to determine what medication was being taken and what was not. In many cases the medical providers and the psychiatric providers had never communicated and there was redundancy and drug interactions. My job in that situation was to make the best estimate of what medications could be safely started and to follow the patient closely so that they could be adjusted. That requires a good knowledge of medications that are used to treat endocrine/metabolic conditions, infectious diseases, rheumatic disorders, gastrointestinal disorders, cardiac conditions, dermatology conditions, chronic pain and neurological conditions.

In other words, most medications that are commonly used. And why wouldn’t psychiatrists prescribe everything both inside and outside of the specialty?  I have been fortunate enough to work with many Internal Medicine specialists and subspecialists. I have witnessed what happens when they encounter a medication that they do not routinely prescribe. They ask the patient about why it was prescribed and their experience with it.  They read the package insert and decide whether to prescribe it or not.  The idea that each specialty has limited knowledge about prescribing medications outside of that specialty seems like an erroneous assumption to me.  It is even clearer now that we have nonphysician prescribers with less basic science and pharmacology knowledge and less supervised prescribing training not restricted to any set group of medications. Physicians have been trained in all classes of pharmacology and should have worked out a general approach on how to safely prescribe any medication encountered.  Physicians also need to know about the range of medications in the population they are working with.  Adapting to the medications utilized by different populations is all part of the practice of medicine.  Today and in the future it is conceivable that a typical psychiatrist may cycle through 4 or 5 different practice scenarios, each one requiring unique a unique knowledge of pharmacology.

That does not mean that I am going to start diagnosing and treating arrhythmias like a cardiologist.  But it does mean that if I get a patient admitted to my inpatient service who is taking an antiarrhythmic that I should be able to decide to continue or restart it, what monitoring needs to be done, whether an ECG needs to be ordered, whether to get a Cardiology consultation or contact the patient’s cardiologist (stat or electively), and whether any medication I want to start or change will affect either the antiarrhythmic or the patient’s underlying cardiac condition. The same process is true for every medication on their list.

The typical argument I encounter with that suggestion is: “Well most psychiatrists don’t practice in that kind of intense medical environment.”  My answer is – open your eyes. It is not enough to look at a typical list of medications in an electronic health record (EHR) and focus only on the ones that psychiatrists should prescribe.  It is not enough to assume that your patient’s list of medical problems is being adequately addressed.  Psychiatry from my perspective still means that the psychiatrist has some responsibility for the total medical care of the patient. In today’s fragmented medical care environment, the psychiatrist may be the only physician the patient is seeing. When asked who their doctor is – many people will name their psychiatrist.

That opinion is bound to make some psychiatrists nervous. They may have the thought; “How can I provide that level of care when I am being reimbursed less and have to spend most of my time doing clerical work for the EHR?” That is a fair question and one without an obvious answer. If administrators were really interested in quality care, they would give primary care physicians and psychiatrists enough time for that level of analysis. Psychiatrists need more time to establish and attend to their relationship with the patient.  But the medical stability of the patient and assuring that they are not experiencing adverse effects and that treatment is effective is an absolute priority. 

Psychiatrists need to be trained to make these assessments and they need to be able to prescribe and modify a significant pharmacopeia extending well beyond what exists in a psychopharmacology text. That skill is predicated on the extensive content in basic science and clinical literature on pharmacology and also the process of learning about new drugs and how to safely prescribe them. That learning process is largely implicit and not discussed enough.  If it was, it could be applied to older medications as well.    

 

George Dawson, MD, DFAPA

 

Supplementary:

I need to add a comment to this post because a lot of practice settings are designed to support specific prescription practices.  For example, there are a lot of private practices that focus primarily on the treatment of anxiety and depression.  There is also the assumption that more complicated pharmacotherapy such as the prescription of lithium needs referral out to a psychopharmacologist. In other cases, clinics will specialize in prescribing that fits specific diagnoses rather than the universe of psychiatric disorders.  Those practices stand in contrast to patients who are unable to get adequate medical or psychiatric care and routinely have their prescriptions disrupted. 

When that does happen they can end up in between prescriptions, self rationing prescriptions, or just not taking any prescribed medication for a while. Depending on the underlying medications, that alone can precipitate a crisis that any psychiatrist or trainee should be able to recognize and address. 

The first place that kind of training occurs is during the admission and coverage of inpatient units. The first orientation to these units should be a discussion of the expectations for prescribing to inpatients in acute care settings. It is not a question of waiting for a physician to sort things out the next day or hoping that a medical consultant will see the patient and make the necessary changes.  Each physician and trainee in that setting needs to know how to make acute assessments, determine the need for medications, and either make those changes or figure out how to get help on an acute basis.  Recognizing the urgency of situations like prescribing insulin for diabetes mellitus is as important as knowing the pharmacology.  Nobody should leave trainees guessing on their first call night.


References:

1:  Balon R, Morreale MK, Aggarwal R, Coverdale J, Beresin EV, Louie AK, Guerrero APS, Brenner AM. Responding to the Shrinking Scope of Psychiatrists' Prescribing Practices. Acad Psychiatry. 2022 Dec;46(6):679-682. doi: 10.1007/s40596-022-01705-1. PMID: 36123516.


Photo Credit:

Eduardo Colon, MD. - many thanks.